Eli Lilly has shared positive two-year results from an open-label extension (OLE) study of Omvoh (mirikizumab-mrkz) in active ...

Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has approved Omvoh® (mirikizumab-mrkz) for the treatment of moderately to severely active Crohn ...

Lilly has its hopes pinned on approval of mirikizumab in inflammatory bowel diseases, after it decided to abandon development of the drug in psoriasis, saying the market had become too crowded ...

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/105.DozQrLpG.js ...

In addition, 40% of mirikizumab patients achieved resolution or near resolution of bowel urgency, considered to be one of the most distressing symptoms of UC, said Lilly. The drug performed better ...

Eli Lilly presents positive results from VIVID-2 open-label extension study of Omvoh to treat Crohn's disease at Crohn's and Colitis Congress: Indianapolis Monday, February 10, 20 ...

Inspira Achieves Positive Results of Above 95% For Preventing Bloodstream Infections Inspira announced its bio-electronic ...

INDIANAPOLIS—Lilly Endowment Inc., a major shareholder in Eli Lilly & Co. (NYSE:LLY), has recently sold a significant portion ...

CNW/ - Pharmascience Canada is proud to announce the launch of  Pr  pms-RUPATADINE (rupatadine), a treatment that helps relieve nasal and non-nasal ...

Before rehabilitation (left), Casey Innalls was using ketamine every day Every generation seems to have an association with an illegal drug. Baby boomers had LSD, Gen X had pills and millennials ...

Need to identify a tablet or capsule? Use our Pill Identifier to find the name and image of an unknown prescription or over-the-counter medication. Start by entering details like pill imprint code ...